Collectively, KRAS mutations profoundly reshape the proteomic, metabolic, signaling, and TME landscapes of cancer cells, driving tumor aggressiveness, altering immune responses, and influencing therapeutic outcomes—highlighting the need for mutation-specific and context-aware strategies in KRAS-targeted cancer treatment. The gene discussed is KRAS; the disease is neoplasm.